Clinical Trial Update: Surufatinib Combined With Tislelizumab in the Second-line and Further Treatment of Triple-negative Breast Cancer [Phase 1, Phase 2]

View source ↗

Summary

A clinical trial update for surufatinib combined with tislelizumab in second-line and beyond for metastatic triple-negative breast cancer (Phase 1/Phase 2).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• Surufatinib (Surufatinib)
• Tislelizumab (tislelizumab)

Snippet

Sponsor: Huihua Xiong | Conditions: Metastatic Triple-negative Breast Cancer | Phase 1, Phase 2 | Status: UNKNOWN